

Professor Jörg M. Fegert
President
European Society for Child and Adolescent Psychiatry
Kroonlaan 20
1050 Brussel
Belgium

WHO Expert Committee on Selection and Use of Essential Medicines
emlsecretariat@who.int

Re: Application reference “A.19 Methylphenidate – attention deficit hyperactivity disorder”

13 March 2025

To whom it may concern

The European Society for Child and Adolescent Psychiatry (ESCAP) strongly supports the inclusion of methylphenidate in the WHO Model List of Essential Medicines and the corresponding application **“A.19 Methylphenidate – attention deficit hyperactivity disorder”**. Together with 15 other national or international professional groups and lived experience associations, we endorsed the correspondence [“WHO Model Lists of Essential Medicines: methylphenidate for ADHD in children and adolescents”](#) published in The Lancet in October 2023. In April 2024, we then published an ESCAP Communication [“ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines”](#) in our journal European Child and Adolescent Psychiatry.

Please do not hesitate to contact us if you have any questions.

Yours sincerely



Jörg M. Fegert
ESCAP President